Innate lymphoid cells activated by the cytokine TL1A link colitis to emergency granulopoiesis and the recruitment of tumor-promoting neutrophils

Read full text
Authors: Sílvia Pires, Wei Yang, Sofía Frigerio, Cynthia Louis, Chloe Scott, Yu Lin Zhou, Emre Cardakli, Nancy Tran, Mina Hassan-Zahraee, Zhan Ye, Craig Hyde, Kenneth Hung
+11 more Amanda Chen, Charles Ng, Alexander Grier, Dana J. Lukin, Ellen Scherl, Stephan R. Targan, Gretchen E. Diehl, Joep Grootjans, Tracy L. Putoczki, Ian P. Wicks, Randy Longman
Cited by: 9
References: 88

Abstract

Inflammatory bowel disease (IBD) increases the risk of colorectal cancer (CRC). Genetic variants in TNFSF15, encoding tumor necrosis factor (TNF)-like cytokine 1A (TL1A), associate with severe IBD and advanced CRC. Here, we investigated how TL1A signaling promotes colitis-associated tumorigenesis. Deletion of the TL1A receptor in tissue-resident type 3 innate lymphoid cells (ILC3s) reduced colitis-associated tumorigenesis. TL1A signaling promoted neutrophil recruitment to the colon, which was required for tumor development. TL1A-stimulated ILC3s activated neutrophils, inducing a tumor-associated neutrophil (TAN)-like gene signature, and transfer of these neutrophils was sufficient to promote tumor growth. A similar TAN-like gene signature was enriched in human colitis-associated dysplasia but reduced following TL1A blockade in ulcerative colitis patients. Mechanistically, TL1A and colitis triggered emergency granulopoiesis, expanding granulocyte-monocyte progenitors and neutrophils in a manner dependent on ILC3-derived granulocyte-macrophage colony-stimulating factor (GM-CSF). Thus, a TL1A-ILC3-GM-CSF axis links colitis with emergency granulopoiesis and may serve as a therapeutic target to reduce colitis-associated CRC.

Fields of Study & Subjects

IL-33 ST2 and ILC Pathways Immune cells in cancer Eosinophilic Esophagitis

Publication details

Journal / source
Immunity
Publisher
Elsevier BV
Volume
59
Issue
2
Pages
372–387.e7
Publication date
22 January 2026
Language
EN